A smartphone game built to reward healthy daily habits helped adults with depression feel better and stick to their medication, according to a Swedish trial published in the Journal of Affective Disorders.
Reports of the findings appeared this week.
Researchers from Linköping University and other institutions in Sweden tested Fig: The Game for Depression, an app developed by Mindforce Game Lab. The paper lists Josefin Brehmer, Matilda Berg and Gabriel Astudillo among its eight authors. In a nine-week randomised trial of 148 adults already taking antidepressants but still experiencing symptoms, roughly half were assigned to play the game while the rest joined a waiting list, Gizmodo reported on November 17.
About 51% of the game players saw at least a 30% reduction in depressive symptoms, compared with about 19% of the control group. The players also reported better medication adherence and a greater reduction in co-existing anxiety symptoms, though researchers did not find a clear improvement in overall quality of life, Knowridge Science Report noted.
Although antidepressants remain among the most widely used treatments, many patients continue to experience residual symptoms, and adherence is not always ideal — which is why researchers have been looking for supportive tools to pair with medication.

Fig turns everyday routines into progress inside a virtual world. Players record whether they have taken their medication, slept regularly, eaten meals and been physically active, then watch their digital surroundings change as the habits build.
The app includes 25 optional modules based on cognitive-behavioral therapy techniques, mood tracking, a personal journal and messaging access to a therapist on demand. A character named Fig offers supportive conversations about mindfulness and negative thinking patterns, with dialogue prepared by psychology specialists and doctors, Alghad reported, citing Medical Express. Players are meant to check in twice a day, in short sessions.

It was made with input from psychiatrists, according to Gizmodo.
The trial was open-label, meaning everyone knew which group they were in, and the results rested on self-reported assessments over a short period.
Completion was also uneven: about 80% of the treatment group downloaded Fig, but only about 60% finished the study and reported how they felt, against 82% of the control group, Gizmodo reported. Knowridge put the gap another way — around 41% of the digital-support group did not complete the final survey, compared with 18% of the waiting group.
| Measure at trial’s end | Game group | Control group |
|---|---|---|
| At least 30% reduction in depressive symptoms | About 51% | About 19% |
| Completed the study and final responses | About 60% | 82% |
The app is now available through the Google Play Store and Apple’s App Store, with a 14-day free trial and a price of $7.99 (USD) a month, Gizmodo reported. It is designed to complement existing treatment, not to replace medication or professional care — a point the Arabic-language coverage also stressed, with Alghad describing Fig as a supportive tool rather than a substitute for medical follow-up.